Astellas Submits New Drug Application for Zolbetuximab in Japan

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the submission of a New Drug Application (NDA)...

Related Keywords

Japan ,Canada ,United States ,Shitara ,Aichi ,United Kingdom ,Tokyo ,Masaka ,Saitama ,Australia ,American ,America ,Naoki Okamura ,Pranob Bhattacharya ,American Cancer Society ,National Cancer Institute ,Ministry Of Health ,Astellas Pharma Inc ,Oncology Development ,End Results Program ,Drug Application To Japan Ministry Of Health ,Prnewswire Astellas Pharma Inc ,American Society Of Clinical Oncology ,Japan Ministry Of Health ,New Drug Application ,Executive Director ,Interim Head ,Immuno Oncology Development ,Locally Advanced Unresectable Metastatic Gastric ,Gastroesophageal Junction ,South America ,Clinical Oncology ,Cancers Symposium ,Plenary Series ,Primary Focus ,Focus Area Approach ,End Results ,